Sessa Capital (Master), L.P. Sab Biotherapeutics, Inc. (SABS) insider trading activity

Sessa Capital (Master), L.P. is Director of SAB Biotherapeutics, Inc.. Currently has a direct ownership of 2.2 Million shares of SABS, which is worth approximately $6.6 Million. The most recent transaction as insider was on Sep 29, 2025, when has been sold 1,740,000 shares (Common Stock) at a price of $1.75 per share, resulting in proceeds of $3,045,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.2M

52.05% 3M change

52.05% 12M change

Total Value Held $6.6 Million

Sessa Capital (Master), L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Sep 29 2025	BUY Exercise of conversion of derivative security	$3,045,000 $1.75 p/Share	1,740,000 Added 44.18%	2,198,457 Common Stock
Nov 24 2023	BUY Exercise of conversion of derivative security	-	4,584,571 Added 50.0%	4,584,571 Common Stock

Also insider at

PRVB

Provention Bio, Inc. Healthcare

> 10% Shareholder

SC(